• SPX
  • $5,792.04
  • 0.71 %
  • $40.91
  • DJI
  • $42,512.00
  • 1.03 %
  • $431.63
  • N225
  • $39,277.96
  • 0.87 %
  • $340.42
  • FTSE
  • $8,243.74
  • 0.65 %
  • $53.13
  • IXIC
  • $18,291.62
  • 0.6 %
  • $108.70
Lineage Cell Therapeutics, Inc. (LCTX) Stock Price, News & Analysis

Lineage Cell Therapeutics, Inc. (LCTX) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.88

$0.01

(1.3%)

Day's range
$0.85
Day's range
$0.89
50-day range
$0.7665
Day's range
$1.06
  • Country: US
  • ISIN: US53566P1093
52 wk range
$0.77
Day's range
$1.61
  • CEO: Mr. Brian M. Culley M.A., M.B.A.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -3.14
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (LCTX)
  • Company Lineage Cell Therapeutics, Inc.
  • Price $0.88
  • Changes Percentage (1.3%)
  • Change $0.01
  • Day Low $0.85
  • Day High $0.89
  • Year High $1.61

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

  • Last Earnings N/A
  • Ex-Dividend for 5/16 Dividend 12/15/2003
  • Dividend Payable N/A
  • Today N/A
  • Next Earnings (Estimated) 11/06/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.13
  • Trailing P/E Ratio -7.46
  • Forward P/E Ratio -7.46
  • P/E Growth -7.46
  • Net Income $-21,486,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.